지엘팜텍
Financials
Valuation Metrics
지엘팜텍's Market Cap is ₩538B. At end of 2025 it was ₩846B. Ranked #1664 of 2,405 in KR market (top 69%), #994 of 1,627 on KOSDAQ (top 61%), #181 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 78%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 53.82B KRW | KR#1,664/2,405 Sec#181/231 |
| Revenue | 38.21B KRW | KR#1,930/2,405 Sec#135/231 |
| Net Income | -107.1M KRW | KR—/2,405 Sec—/231 |
| Total Assets | 49.00B KRW | KR#2,205/2,405 Sec#201/231 |
| Net Assets | 19.89B KRW | KR#2,279/2,405 Sec#213/231 |
| Employees | 25 | KR#2,210/2,405 Sec#208/231 |
| Value | ||
| P/B | 2.71x | KR#2,102/2,405 Sec#164/231 |
| P/S | 1.41x | KR#1,664/2,405 Sec#98/231 |
| EV/EBITDA | 336.92x | KR#1,543/2,405 Sec#108/231 |
| FCF Yield | -8.04% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -0.54% | KR#1,585/2,405 Sec#109/231 |
| ROA | -0.22% | KR#1,574/2,405 Sec#109/231 |
| Op. Margin | 0.59% | KR#1,548/2,405 Sec#110/231 |
| Revenue Growth | 29.75% | KR#393/2,405 Sec#39/231 |
| Earnings Growth | -288.02% | KR#1,262/2,405 Sec#89/231 |
| Financial Health | ||
| Debt Ratio | 146.38% | KR#1,872/2,405 Sec#207/231 |
| Total Debt | 24.97B KRW | KR#1,305/2,405 Sec#105/231 |
| FCF | -4.33B KRW | KR#1,462/2,405 Sec#116/231 |
| Cash | 3.25B KRW | KR#2,137/2,405 Sec#202/231 |
| Current Ratio | 0.98x | KR#1,735/2,405 Sec#174/231 |
| Net Debt/EBITDA | 96.88x | KR#1,516/2,405 Sec#106/231 |
| Performance | ||
| 1Y Return | -42.21% | KR#1,754/2,405 Sec#146/231 |
| 1M Return | -17.38% | KR#1,715/2,405 Sec#168/231 |
| From 52W High | -47.06% | KR#1,040/2,405 Sec#73/231 |
| 1Y MDD | -46.15% | KR#787/2,405 Sec#58/231 |
| Trading | ||
| Volume | 17,163 shares | KR#1,578/2,405 Sec#156/231 |
| Trading Value | 59.3M KRW | KR#1,646/2,405 Sec#172/231 |
| Foreign Own. | 0.74% | KR#2,121/2,405 Sec#208/231 |
| Per Share | ||
| EPS | -7 KRW | KR—/2,405 Sec—/231 |
| BPS | 1,282 KRW | KR#2,241/2,405 Sec#201/231 |
Company Info
GL Pharm Tech, established in 2014 and headquartered in Seongnam-si, Gyeonggi-do, is a specialized enterprise in pharmaceutical research and development services and sales & marketing, listed on KOSDAQ in 2014. The company focuses on developing incrementally modified drugs using Drug Delivery System (DDS) technologies like controlled release and drug absorption enhancement. Its consolidated subsidiary, GL Pharma Co., Ltd., possesses hormone drug production facilities, which only a few domestic pharmaceutical companies have, and produces and sells pharmaceuticals, expanding its business into contract manufacturing and sales.